https://www.selleckchem.com/products/vx-661.html
PURPOSE To determine the efficacy, risk factors for failure, and adverse events of a standalone novel ab-externo SIBS microshunt with mitomycin C (MMC) during 1-year follow-up. DESIGN Retrospective, interventional case series. SUBJECTS Glaucomatous eyes with an IOP above target and/or progressing on maximally tolerated medical therapy. METHODS Consecutive patients with open angle glaucoma (OAG) and no previous filtering surgery received an ab-externo SIBS microshunt with MMC from July 2015 to November 2017. MAIN OUTCOME MEASURES Proporti
Like
Comment
Share
